Core Insights - The research led by Chinese scientists reveals that extracellular vesicles from antler blastema progenitor cells can reverse bone loss and mitigate aging-related phenotypes in mice and macaques, providing a new treatment strategy for age-related diseases such as Alzheimer's and osteoporosis [1][3][11] - The findings are expected to drive the traditional deer industry towards biotechnology, creating a new ecosystem that combines ancient Chinese medicine wisdom with modern biotechnological advancements [3][4][18] Company Overview - Jilin Aodong (000623) is the largest deer product processing company in China, with over 60 years of experience in breeding sika deer and continuous research on deer antler [3][4][18] - The scientific discoveries related to deer antler have validated the traditional efficacy of Jilin Aodong's product, Anshen Bnona Liquid, which is believed to contain "longevity" secrets that will be gradually unveiled with the research outcomes [3][12][16] Market Potential - Jilin Aodong aims to integrate traditional deer antler value with cutting-edge biotechnology, potentially capturing a significant share of the "brain health" market, which is projected to be worth hundreds of billions [4][18] - The company has a strong foothold in the market, holding 60%-70% of the national market share for Anshen Bnona Liquid, which generates over 700 million yuan in annual sales [16][17] Research and Development - The research on deer antler regeneration has opened new avenues for anti-aging interventions, particularly in reversing bone loss and improving multi-organ aging [11][19] - Jilin Aodong has been actively investing in research and development, achieving breakthroughs in deer breeding technology and establishing a comprehensive disease prevention system [19][20] Policy Support - The company benefits from favorable government policies aimed at promoting the deer industry, including the recent development plan for the sika deer industry (2025-2029) that encourages the exploration of classic formulas and modern biotechnological applications [20][21] - Jilin Aodong has already obtained GMP compliance and "blue hat" certification for its health products, positioning itself well to leverage policy support for quality enhancement [20]

Group 1: Health Impacts of High Temperatures - Extreme heat poses significant health risks, including heatstroke and accelerated aging processes in humans [1] - High temperatures induce oxidative stress, disrupt protein homeostasis, activate inflammatory pathways, and directly age skin and organs [1][3] - Chronic inflammation triggered by high temperatures can silently damage various body tissues [3] Group 2: Antioxidant Properties of Astaxanthin - Astaxanthin, a potent antioxidant, can penetrate cell membranes and effectively neutralize free radicals throughout the body [3] - It inhibits the production and release of inflammatory factors such as IL-6 and TNF-α, providing a balanced anti-inflammatory effect [3][5] - Astaxanthin offers protective benefits against UV-induced skin damage, reducing the penetration and harm caused by UVA and UVB rays [5] Group 3: Industry Leadership and Product Development - Green A Bio is a leading player in the astaxanthin industry, having developed proprietary technologies that break the technological monopoly held by the US and Japan [7] - The company has launched innovative products, including the "Red A Aista" and the anti-aging astaxanthin series, which combine natural astaxanthin with GABA and collagen peptides [7] - The growing medical research on astaxanthin suggests expanding applications in anti-aging and disease prevention, positioning it as a key health supplement [7]

Core Viewpoint - Bryan Johnson, a Silicon Valley entrepreneur, is dedicated to anti-aging and longevity, investing significantly in various health technologies and practices to reverse his biological age and promote a healthier lifestyle [1][2][3]. Group 1: Personal Journey and Philosophy - Johnson's journey into anti-aging began after selling his company for nearly $1 billion, leading him to explore how to live a more meaningful life [4][5]. - He emphasizes the importance of scientific measurement in health, advocating for a data-driven approach to understanding and improving personal health metrics [12][18]. - The concept of "Don't Die" is framed as a universal call to action, transcending cultural and ideological differences, focusing on the shared human desire to live [26][27]. Group 2: Health Practices and Findings - Johnson follows a strict regimen that includes low-calorie intake, regular exercise, and extensive supplementation, claiming that foundational practices like sleep, diet, and exercise account for 80% of health outcomes [19][21][36]. - He has publicly shared over 60 biomarkers related to health and longevity, aiming to create a measurable standard for health that can be replicated by others [13][34]. - The focus on resting heart rate before bed is highlighted as a key indicator of overall health, with specific recommendations for improving it through lifestyle changes [20][21]. Group 3: Community and Cultural Impact - Johnson has created support groups to foster accountability and community among individuals striving to improve their health, emphasizing the importance of social support in achieving health goals [24][25]. - He aims to shift cultural perceptions around health, making good health practices socially desirable and recognized [23][34]. - The initiative to establish a "Rejuvenation Olympics" encourages experimentation with various therapies to discover effective methods for slowing aging [31][34].

Group 1 - Xinhua Medical's subsidiary has received a Class II medical device registration certificate for its thoracic and abdominal endoscope, enhancing its product offerings in minimally invasive surgery [1] - The successful registration of the thoracic and abdominal endoscope enriches Xinhua Medical's portfolio and creates new market growth opportunities [1] Group 2 - Sino-Pharmaceutical has signed a joint research and licensing agreement with Gero PTE to develop new therapies for age-related diseases, involving potential payments of up to $250 million [2] - The collaboration reflects significant market interest and investment potential in the field of age-related disease treatments, combining Gero's AI-driven technology with Sino-Pharmaceutical's resources [2] Group 3 - Yiling Pharmaceutical's G201-Na capsule, a new chemical drug for controlling ovulation in assisted reproductive technology, has received approval for clinical trials [3] - The approval marks a significant breakthrough in Yiling Pharmaceutical's drug development, targeting a market with substantial potential [3] Group 4 - Hainan Haiyao plans to accept financial support from its controlling shareholder, with a maximum amount of RMB 500 million, to stabilize operations and enhance market confidence [4] - The financial assistance, with an annual interest rate of 5%, will be used for the company's main business and to supplement working capital [4]

Core Viewpoint - Google’s subsidiary Calico Life Sciences has entered into a nearly $600 million biopharmaceutical deal with Mabwell to acquire rights to a research therapy targeting Interleukin-11 (IL-11), including a clinical-stage monoclonal antibody 9MW3811 for age-related diseases [2][3]. Group 1: Deal Details - Mabwell has explored the therapeutic potential of 9MW3811 in age-related diseases during preclinical research, completing Phase 1 clinical studies in China and Australia, showing promise for treating idiopathic pulmonary fibrosis, and has received approval to conduct Phase 1 clinical studies in the United States [3]. - Under the licensing agreement, Mabwell grants Calico exclusive rights to develop, manufacture, and commercialize 9MW3811 outside Greater China. Calico will pay an upfront non-refundable fee of $25 million, with potential additional payments of up to $571 million based on milestones, as well as tiered royalties based on net sales of the licensed product [3]. Group 2: Company Background - Calico was co-founded by Alphabet, Google's parent company, and industry leader Dr. Arthur Levinson, with the aim of understanding the biological principles of aging to help develop interventions that extend and improve lifespan. Calico has established partnerships with several organizations, including AbbVie and the Broad Institute of MIT and Harvard [3]. - Mabwell is an innovative biopharmaceutical company with a full industry chain layout, focusing on tumors and age-related diseases, covering treatment areas such as oncology, autoimmune diseases, bone diseases, ophthalmology, hematology, and infections [4].

Industry Overview - The Chinese medical beauty market is projected to reach 312 billion yuan in 2024, representing a growth of 14.8% compared to 2023 [1] - The demand for medical beauty in China is still on the rise, with a notable increase in male participation in the sector [3][5] Market Trends - The global medical beauty industry shows that the United States leads in the number of procedures, followed by Brazil, Japan, China, and India [3] - Common procedures for women include liposuction, breast augmentation, eyelid surgery, abdominal contouring, and breast lift, while men primarily undergo eyelid surgery and gynecomastia correction [3] Consumer Behavior - Many individuals pursue medical beauty not solely for aesthetics but also for self-confidence enhancement [6] - There is a growing trend among younger generations to invest time in beauty routines, raising questions about the motivations behind such practices [6][12] Psychological Aspects - The aging process is a natural phenomenon, and while medical beauty can delay visible signs of aging, it cannot prevent them [7] - The perception of beauty and self-worth is increasingly influenced by societal standards and media portrayals, leading to a complex relationship between self-esteem and appearance [6][12] Aesthetic Diversity - There has been a shift from a homogenized beauty standard, often referred to as "internet celebrity face," to a more diverse representation of beauty in media and entertainment [9] - The industry is moving towards emphasizing individual features rather than conforming to a singular aesthetic [9] Private Aesthetic Procedures - Private aesthetic procedures, particularly in the genital area, are gaining attention, with a focus on addressing both medical and cosmetic needs [14][15] - There is a need for better education and destigmatization surrounding these procedures, as many women may have legitimate health concerns that require attention [15][16]

Core Viewpoint - The research highlights the potential of genetically engineered human mesenchymal progenitor cells (SRC) to counteract aging in primates, suggesting a new paradigm for anti-aging cell therapy [2][12]. Group 1: Aging Mechanism and Cell Therapy - The study investigates the mechanisms of aging regulation and employs synthetic biology to reprogram longevity gene pathways, successfully creating SRC with triple resistance to aging, stress, and malignant transformation [3][7]. - SRC cells exhibit significant anti-aging activity and strong environmental adaptability, while also demonstrating excellent safety features to avoid tumorigenic risks post-transplantation [8]. Group 2: Experimental Results - In a 44-week trial involving elderly crab-eating macaques (equivalent to 60-70 years in human age), SRC therapy resulted in reduced systemic aging indicators, such as cellular senescence, chronic inflammation, and tissue degeneration, with no adverse reactions detected [10]. - Notably, SRC treatment improved brain structure and cognitive function, reversing the biological age of immature neurons by 6-7 years and oocytes by 5 years, as confirmed by machine learning-based aging clock analysis [10]. Group 3: Mechanism of Action - The restorative effects of SRC are partially attributed to their exosomes, which play a crucial role in promoting cellular rejuvenation, inhibiting chronic inflammation, and maintaining genomic and epigenomic stability, providing new insights into pathways for delaying systemic aging [10].

Core Insights - The health industry is experiencing significant growth, with products derived from sika deer gaining popularity due to their unique nutritional and medicinal values [1] - The establishment of Zunxi Deer Biotechnology Research Institute (Hubei) focuses on comprehensive research of sika deer products, particularly in quality testing and component analysis, laying a solid foundation for the healthy development of the sika deer industry [1] Component Analysis - Sika deer products contain complex components beneficial to human health, prompting the formation of a specialized research team at Zunxi Deer Biotechnology Research Institute, comprising experts from biochemistry, pharmacy, and nutrition [2] - Research on deer antler revealed that every 100 grams contains 50-60 grams of amino acids, including all eight essential amino acids, and 10-15 grams of peptides with varying biological activities [2] - The presence of "uridine" in deer antler shows significant effects in animal experiments, enhancing stem cell vitality and improving aging indicators when administered at a dosage of 50 mg per kg body weight [2] Blood Component Analysis - Advanced blood component analysis techniques were employed to study deer blood, revealing that immunoglobulin levels are 2-3 times higher than in ordinary animal blood, indicating strong immune-regulating properties [3] - The optimal conditions for superoxide dismutase (SOD) activity in deer blood were found to be at pH 7.0-7.5 and 37°C, effectively clearing free radicals and reducing oxidative stress [3] - The synergistic effect of hemoglobin and other active components in deer blood enhances nutrient absorption and utilization in the human body [3] Industry Advancement - The research outcomes from Zunxi Deer Biotechnology Research Institute are being transformed into practical applications, driving the upgrade of the sika deer industry [4] - New products have been developed based on the understanding of sika deer product components, such as deer antler essence skincare products and deer blood products combined with other health ingredients to meet diverse consumer health needs [4] - The institute's research supports the establishment of standardized quality and testing methods for sika deer products, promoting market order and healthy development of the industry [4] - Continuous exploration and practice in component analysis inject innovation into the sika deer industry, enhancing product quality and market competitiveness [4]

神译局是36氪旗下编译团队，关注科技、商业、职场、生活等领域，重点介绍国外的新技 术、新观点、新风向。 编者按：40+人群如何科学延缓衰老？本文从神经生物学、新陈代谢角度切入，拆解晨间习惯对衰老的 深层影响，提供可落地的5大抗衰方案。让我们回归科学本质，用每一个日常选择来让细胞焕发新生 吧。文章来自编译。 你有没有怀疑过自己早上的习惯反而会让你老得更快？ 事实上，起床后第一个小时做的事，会直接影响你变衰老的速度。 明明睡够了8小时，醒来却像没睡过一样？跌跌撞撞爬起来喝咖啡刷手机，浑浑噩噩过一天？ 但你可能不知道——正是这些习惯让你越活越累、压力变大，甚至加速变老。 虽然听起来夸张，但你起床的方式、喝水习惯、动不动身子、早餐吃什么，都会实实在在影响你的精 力、皮肤状态和衰老速度。 如果做得不对，你会一整天都昏昏沉沉、皮肤暗黄、有气无力。如果做得对，不用花里胡哨的操作，就 能保持头脑清醒、容光焕发。 下面就来揪出5个常见错误（附解决办法），帮助你轻松开启活力满满的一天： 为什么每天起床都像没睡醒？ 睡了8小时还是困得睁不开眼，甚至想再睡8小时？ 这种似睡非睡的状态叫"睡眠惯性"——你的身体醒了，但大脑还没醒。部分 ...

Core Viewpoint - The ongoing dispute between renowned biologist Rao Yi and Kelun Pharmaceutical regarding the classification of ergothioneine as a "fake drug" has escalated, with Kelun asserting that ergothioneine is recognized internationally as a dietary supplement rather than a drug, thus negating the "fake drug" claim [1][12]. Company Response - On June 6, Kelun Pharmaceutical published a response on its official WeChat account, stating its commitment to clarify misunderstandings with rigorous scientific data and emphasizing that ergothioneine is a health management tool [1]. - Kelun cited various authoritative journals and clinical studies to support its claims about ergothioneine's benefits, including research from the Leibniz Institute and Harvard Medical School, which suggest ergothioneine can mediate healthy aging through dual mechanisms [6][9]. Market Reaction - Following the controversy, Kelun Pharmaceutical's stock price fell by 0.74% to 37.47 yuan per share, resulting in a market capitalization of 598.79 billion yuan [2]. Clinical Evidence - Kelun referenced multiple clinical trials conducted in Japan, Singapore, and Sweden, demonstrating ergothioneine's efficacy in areas such as sleep health, cognitive health, skin anti-aging, and cardiovascular health [7][9]. - The results of these trials were published in reputable journals, with three out of four being top-tier in their respective fields [9]. Regulatory Context - Ergothioneine has been recognized as a novel food supplement in several countries, including the U.S. and Japan, with the U.S. FDA granting it GRAS (Generally Recognized As Safe) status [9]. - However, it is noted that while the National Health Commission of China has accepted an application for ergothioneine as a new food ingredient, it has not yet been approved [9]. Scientific Debate - Rao Yi challenged Kelun's claims, stating that without approval from the National Medical Products Administration, the promotion of ergothioneine could be misleading or deceptive [5][12]. - Kelun responded by arguing that the approval process for drugs differs from that of dietary supplements, emphasizing that ergothioneine serves a different purpose in health management [12].